OBJECTIVES Ophthalmology pharmaceutical market is growing worldwide due to rising aging population, new delivery technologies and changing lifestyle. However, challenges like patent expiry of major brands and lack of awareness still persists. Therefore, it is important to be aware of the upcoming treatment options, changing patients’ needs and requirement of cost effective therapies. This analysis provides an overview of the recent trends and future scenario in Ophthalmology market. METHODS Pharmaceutical companies sponsored clinical trials initiated from January 2011 to April 2014 in Glaucoma, Age-related Macular Degeneration (AMD), Diabetic Retinopathy (DR)/ Diabetic Macular Edema (DME), Dry eye syndrome (DES) and Retinal vein occlusion (RVO) have been considered. Only Phase I - III trials listed on public registries have been considered. RESULTS The data showed that >30% of the trials are being conducted on Glaucoma in USA, Europe, Asia and Australia. This is followed by AMD (24%), DR/DME (21%), DES (17%) and RVO (7%). Also,>50% ophthalmological trials are being conducted in USA; followed by Europe (~25%) and Asia (~20%).In Europe, 71 trials have been conducted on 48 molecules, of which 69% are chemical entities, 19% are biologicals and >10% are entities like RNAi (oligonucleotide, aptamers), DARPin. Eye drops (46%) and intravitreal injections (37%) are the key topical and parenteral formulations, respectively. 10% of the trials have been conducted on oral formulations. In Europe, EU5 countries comprise of 43% of the trials and Germany has maximum 37 trials. Novartis has conducted trials in maximum 30 countries, followed by Santen (19), Pfizer (15) and Allergan (13) in Europe. CONCLUSIONS Based on the analysis, currently, Glaucoma, AMD and DR/DME are the major focus of the companies in ophthalmology. Though, biologicals and RNAi are being tested routinely, chemical entities are foremost modalities. Similarly, eye drops remain as preferred method of delivery with respect to other newer delivery techniques.